Is it time for a paradigm shift in drug research and development in endometriosis/adenomyosis?
Open accessThe DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The drug research and development (R&D) for endometriosis/adenomyosis has been painfully slow. Most completed clinical trials on endometriosis did not publish their results, and presumably failed. While few published trials did report how they foundered, the reasons why they failed are often completely unclear. Surprisingly, there has been no open discussion on why these trials failed. If the causes for these failed trials remain unelucidated, mistakes made in these failed trials may be repeated in the future. Since failure can be infinitely more instructive and educational than success, elucidating the causes for failed clinical trials may yield a treasure trove for future drug R&D. Given our growing understanding of the natural history of ectopic endometrium, it is also important to make an inventory of biologicals/compounds that are currently under development to see where we stand and whether they would stand a better chance of gaining regulatory approval than their predecessors. OBJECTIVE AND RATIONALE: We provide an overview of all compounds under clinical investigation and in development in order to assess the evolution of R&D since the last inventory, reported in 2013. We also have attempted to analyse selected failed clinical trials in the context of published translational/preclinical research and our growing understanding of the natural history of endometriotic/adenomyotic lesions, in the hope that the lessons learned will steer investigators toward the right track in future drug R&D. SEARCH METHODS: We searched ClinicalTrials.gov and a database containing information on drugs gathered daily by Thomson Reuters from a wide range of sources (e.g. patent offices, biomedical literature, congresses, symposia, meetings, company information, regulatory information) for all therapeutic compounds that have undergone or are under clinical trials, or in the developmental stage, and then searched PubMed and Google to determine their publication status using trial identifiers. For trials that were completed at least 2 years ago and have, or have not, published their results, a PubMed search was performed using the name of the therapeutic that has been tested and 'endometriosis' or 'adenomyosis' to identify published preclinical studies prior to the launch of the trial. For those published trials, the cited preclinical studies were also retrieved and scrutinized. OUTCOMES: Despite repeated calls for more transparency, only a small fraction of completed trials on endometriosis has been published. A large number of 'novel' compounds under development are simply repurposed drugs, which seem to be ill-prepared to combat the fibroproliferative nature of endometriosis/adenomyosis. This sobering picture indicates an alarming innovation 'drought' in the drug R&D front, resulting in trickling drug pipelines. Some trials foundered owing to unanticipated serious side-effects, or because attempts were made to suppress a target that can be compensated for by redundant pathways, but many failed in efficacy, indicating that the translational value of the current models is seriously questionable. All existing animal models of endometriosis do not recapitulate the key features of human conditions. WIDER IMPLICATIONS: The glaring innovation drought in drug R&D for endometriosis/adenomyosis should sound alarms to all stake-holders. The failed clinical trials in endometriosis also indicate that some past research had serious deficiencies. In light of the recent understanding of the natural history of ectopic endometrium, it is perhaps time to shift the research paradigm and revamp our research focus and priorities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167 · cited 1×
“This is not unusual as most drug development programs fail after reaching the clinical stage, and in this regard Women’s Health programs have the worst performance (Kola and Landis, 2004).”
BackgroundMacrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm
Biswas, S. K., & Mantovani, A. (2010) · Nature Immunology · doi:10.1038/ni.1937 · Cited by 3,840 · cited 2×
“They have at least two distinct states of polarized activation: the classically activated (M1) phenotype and the alternatively activated (M2) phenotype (Gordon and Taylor, 2005; Biswas and Mantovani, 2010).”
BackgroundHow to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566 · cited 1×
“Since clinical trials consume a lion’s share of the drug R&D budget (Paul et al., 2010), and are time- and energy-consuming and logistically challenging to conduct, the decision to advance the R&D program to the clinical stage is not made lightly in industry.”
BackgroundGiudice, L. C., & Kao, L. C. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17403-5 · Cited by 3,166
Publication bias in clinical research
Easterbrook, P. J., Gopalan, R., Berlin, J. A., & Matthews, D. R. (1991) · The Lancet · doi:10.1016/0140-6736(91)90201-y · Cited by 3,109 · cited 1×
“Rather, it is an issue that was made public over 20 years ago (Simes, 1986) and is well documented (Easterbrook et al., 1991; Zarin and Tse, 2008), and still remains a pervasive problem in medicine (Miller et al.”
BackgroundProvenzano, P. P., Cuevas, C., Chang, A. E., Goel, V. K., Von Hoff, D. D., & Hingorani, S. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.01.007 · Cited by 2,195 · cited 1×
“, 2018c), and also because the excessive production of extracellular matrix leads to increased interstitial tissue pressure that impairs blood flow (Lutz et al., 2012; Provenzano et al., 2012).”
BackgroundNnoaham, K. E., Hummelshoj, L., Webster, P., d’Hooghe, T., de Cicco Nardone, F., de Cicco Nardone, C., Jenkinson, C., Kennedy, S. H., & Zondervan, K. T. (2011) · Fertility and Sterility · doi:10.1016/j.fertnstert.2011.05.090 · Cited by 1,584
Macrophages: master regulators of inflammation and fibrosis
Wynn, T., & Barron, L. (2010) · Seminars in Liver Disease · doi:10.1055/s-0030-1255354 · Cited by 1,392
Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., & Pangalos, M. N. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4309 · Cited by 1,344 · cited 2×
“Drug developers at AstraZeneca took a closer look at what stage the projects fail, and why, and it was evident that the project failure rate is highest in the Phase IIa proof of concept phase (Cook et al., 2014).”
BackgroundLiver inflammation and fibrosis
Koyama, Y., & Brenner, D. A. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88881 · Cited by 1,295
Simoens, S., Dunselman, G., Dirksen, C., Hummelshoj, L., Bokor, A., Brandes, I., Brodszky, V., Canis, M., Colombo, G. L., DeLeire, T., et al. (2012) · Human Reproduction · doi:10.1093/humrep/des073 · Cited by 1,070
Effects of Raloxifene on Cardiovascular Events and Breast Cancer in Postmenopausal Women
Barrett-Connor, E., Mosca, L., Collins, P., Geiger, M. J., Grady, D., Kornitzer, M., McNabb, M. A., & Wenger, N. K. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062462 · Cited by 1,048
Dissemination and publication of research findings: an updated review of related biases
Song, F., Parekh, Hooper, L., Loke, Y., Ryder, J., Sutton, A., Hing, C., Kwok, C., Pang, C., & Harvey, I. (2010) · Health Technology Assessment · doi:10.3310/hta14080 · Cited by 1,039
Publication bias: the case for an international registry of clinical trials.
Simes, R. J. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.10.1529 · Cited by 747
Recurrence of endometriosis and its control
Guo, S.-W. (2009) · Human Reproduction Update · doi:10.1093/humupd/dmp007 · Cited by 719
Self-citationCancer-associated mutations in endometriosis without cancer
Anglesio, M. S., Papadopoulos, N., Ayhan, A., Nazeran, T. M., Noë, M., Horlings, H. M., Lum, A., Jones, S., Senz, J., Seckin, T., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614814 · Cited by 628 · cited 1×
“While ectopic endometrium is fundamentally different from normal endometrium (Anglesio et al., 2017), and in fact it is also quite different transcriptionally from eutopic endometrium (Wu et al.”
BackgroundCanonico, M., Plu-Bureau, G., Lowe, G. D. O., & Scarabin, P.-Y. (2008) · BMJ · doi:10.1136/bmj.39555.441944.be · Cited by 569 · cited 4×
“In addition, SERMs block the feedback inhibition of sex steroids on the hypothalamus and pituitary, and the resultant ovarian stimulation and increased estrogen production may have contributed to the failure of the trial (Naqvi et al., 2014).”
BackgroundInfluentialZimmermann, A., Bernuit, D., Gerlinger, C., Schaefers, M., & Geppert, K. (2012) · BMC Women's Health · doi:10.1186/1472-6874-12-6 · Cited by 556 · cited 1×
“Next to uterine fibroids, with an estimated prevalence ranging from 5 to 21% (Zimmermann et al., 2012), endometriosis (prevalence ranging from 6 to 10%, see (Giudice and Kao, 2004)) and adenomyosis (estimated prevalence ~20%, see (Naftalin et al.”
BackgroundMatrix stiffness-induced myofibroblast differentiation is mediated by intrinsic mechanotransduction
Huang, X., Yang, N., Fiore, V. F., Barker, T. H., Sun, Y., Morris, S. W., Ding, Q., Thannickal, V. J., & Zhou, Y. (2012) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2012-0050oc · Cited by 530
Delay in the diagnosis of endometriosis: a survey of women from the USA and the UK
Hadfield, R., Mardon, H., Barlow, D., & Kennedy, S. (1996) · Human Reproduction · doi:10.1093/oxfordjournals.humrep.a019270 · Cited by 517 · cited 2×
“This, coupled with the well documented diagnostic delay in endometriosis (Hadfield et al., 1996; Dmowski et al., 1997), suggests that endometriotic/adenomyotic lesions are mostly highly fibrotic, especially in deep endometriosis (Liu et al.”
BackgroundWound Macrophages as Key Regulators of Repair
Brancato, S. K., & Albina, J. E. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2010.08.003 · Cited by 508
Prediction of endometriosis with serum and peritoneal fluid markers: a prospective controlled trial
Bedaiwy, M. A. (2002) · Human Reproduction · doi:10.1093/humrep/17.2.426 · Cited by 485 · cited 1×
“It is well known that inflammatory cytokines, such as tumor necrosis factor (TNF)-α, are elevated in the blood and peritoneal fluid of women with endometriosis (Eisermann et al., 1988; Bedaiwy et al., 2002).”
BackgroundDe Graaff, A. A., D'Hooghe, T. M., Dunselman, G. A. J., Dirksen, C. D., Hummelshoj, L., WERF EndoCost Consortium, Simoens, S., Bokor, A., Brandes, I., Brodszky, V., et al. (2013) · Human Reproduction · doi:10.1093/humrep/det284 · Cited by 473
Bacci, M., Capobianco, A., Monno, A., Cottone, L., Di Puppo, F., Camisa, B., Mariani, M., Brignole, C., Ponzoni, M., Ferrari, S., et al. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.081011 · Cited by 458
Trial Publication after Registration in ClinicalTrials.Gov: A Cross-Sectional Analysis
Ross, J. S., Mulvey, G. K., Hines, E. M., Nissen, S. E., & Krumholz, H. M. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000144 · Cited by 401
Progesterone resistance in endometriosis: link to failure to metabolize estradiol.
Bulun, S. E., Cheng, Y.-H., Yin, P., Imir, G., Utsunomiya, H., Attar, E., Innes, J., & Julie Kim, J. (2006) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2005.11.041 · Cited by 397
Compliance with Results Reporting at ClinicalTrials.gov
Anderson, M. L., Chiswell, K., Peterson, E. D., Tasneem, A., Topping, J., & Califf, R. M. (2015) · New England Journal of Medicine · doi:10.1056/nejmsa1409364 · Cited by 380
Publication of NIH funded trials registered in ClinicalTrials.gov: cross sectional analysis
Ross, J. S., Tse, T., Zarin, D. A., Xu, H., Zhou, L., & Krumholz, H. M. (2012) · BMJ · doi:10.1136/bmj.d7292 · Cited by 371 · cited 1×
“6% after 5 years, but in the end roughly 30–50% of the studies still remain unpublished (Bourgeois et al., 2010; Ross et al., 2012; Miller, Korn and Ross, 2015).”
BackgroundOutcome Reporting Among Drug Trials Registered in ClinicalTrials.gov
Bourgeois, F. T., Murthy, S., & Mandl, K. D. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-153-3-201008030-00006 · Cited by 332 · cited 1×
“6% after 5 years, but in the end roughly 30–50% of the studies still remain unpublished (Bourgeois et al., 2010; Ross et al., 2012; Miller, Korn and Ross, 2015).”
BackgroundPathogenesis of adenomyosis, an update on molecular mechanisms
Vannuccini, S., Tosti, C., Carmona, F., Huang, S. J., Chapron, C., Guo, S.-W., & Petraglia, F. (2017) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2017.06.016 · Cited by 326
Self-citationRole of Estrogen Receptor-β in Endometriosis
Bulun, S., Monsavais, D., Pavone, M., Dyson, M., Xue, Q., Attar, E., Tokunaga, H., & Su, E. (2012) · Seminars in Reproductive Medicine · doi:10.1055/s-0031-1299596 · Cited by 321 · cited 1×
“…investigators demonstrated that ERβ expression is strongly elevated in endometriotic tissue as a result of demethylation of the gene promoter region (Bulun et al., 2012), and that ERβ, binding to estradiol with the same affinity as ERα, could be a key player in the pathophysiology of endometriosis.”
BackgroundPromoter Hypermethylation of Progesterone Receptor Isoform B (PR-B) in Endometriosis
Wu, Y., Strawn, E., Basir, Z., Halverson, G., & Guo, S.-W. (2006) · Epigenetics · doi:10.4161/epi.1.2.2766 · Cited by 321
Self-citationChwalisz, K., Perez, M. C., DeManno, D., Winkel, C., Schubert, G., & Elger, W. (2005) · Endocrine Reviews · doi:10.1210/er.2005-0001 · Cited by 310
Schmucker, C., Schell, L. K., Portalupi, S., Oeller, P., Cabrera, L., Bassler, D., Schwarzer, G., Scherer, R. W., Antes, G., von Elm, E., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114023 · Cited by 269
Time to redefine endometriosis including its pro-fibrotic nature
Vigano, P., Candiani, M., Monno, A., Giacomini, E., Vercellini, P., & Somigliana, E. (2018) · Human Reproduction · doi:10.1093/humrep/dex354 · Cited by 235 · cited 3×
“In addition, given the fibroproliferative nature of endometriotic lesions (Vigano et al., 2017; Guo, 2018) as well as adenomyotic lesions (Liu et al.”
BackgroundInfluentialEfficacy and safety of repeated use of ulipristal acetate in uterine fibroids
Donnez, J., Hudecek, R., Donnez, O., Matule, D., Arhendt, H.-J., Zatik, J., Kasilovskiene, Z., Dumitrascu, M. C., Fernandez, H., Barlow, D. H., et al. (2015) · Fertility and Sterility · doi:10.1016/j.fertnstert.2014.10.038 · Cited by 216
Zhang, Q., Duan, J., Liu, X., & Guo, S.-W. (2016) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2016.03.015 · Cited by 211 · cited 11×
“…deficiency in mPEGS-1 for instance has been shown to exacerbate pulmonary fibrosis (Wei et al., 2014), raising the question as to whether inhibition could actually exacerbate endometriosis—as it is now also recognized as a pro-fibrotic disorder (Zhang et al., 2016a, b; Vigano et al., 2017).”
BackgroundInfluentialSelf-citationTranscriptional characterizations of differences between eutopic and ectopic endometrium
Wu, Y., Kajdacsy-Balla, A., Strawn, E., Basir, Z., Halverson, G., Jailwala, P., Wang, Y., Wang, X., Ghosh, S., & Guo, S.-W. (2006) · Endocrinology · doi:10.1210/en.2005-0426 · Cited by 208
Progesterone Receptor Isoform A But Not B Is Expressed in Endometriosis1
Attia, G. R., Zeitoun, K., Edwards, D., Johns, A., Carr, B. R., & Bulun, S. E. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.8.6739 · Cited by 193
Liu, X., Shen, M., Qi, Q., Zhang, H., & Guo, S.-W. (2016) · Human Reproduction · doi:10.1093/humrep/dew018 · Cited by 190 · cited 3×
“In addition, given the fibroproliferative nature of endometriotic lesions (Vigano et al., 2017; Guo, 2018) as well as adenomyotic lesions (Liu et al., 2016b, 2018a, c, Shen et al., 2016), there is a real question as to whether SPRMs can have any impact on advanced endometriosis/adenomyosis.”
BackgroundSelf-citationMedical treatment of endometriosis-related pain
Vercellini, P., Buggio, L., Frattaruolo, M. P., Borghi, A., Dridi, D., & Somigliana, E. (2018) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2018.01.015 · Cited by 188
“Waiting for Godot”: a commonsense approach to the medical treatment of endometriosis
Vercellini, P., Crosignani, P., Somigliana, E., Vigano, P., Frattaruolo, M. P., & Fedele, L. (2011) · Human Reproduction · doi:10.1093/humrep/deq302 · Cited by 180 · cited 1×
“Drug research and development (R&D) in endometriosis/adenomyosis has been painfully slow (Guo, 2014), and the disappointment is unmistakable (Vercellini et al., 2011), which becomes painfully clear when looking at the three products that have been launched for the treatment of endometriosis-related symptoms since the…”
BackgroundEndometriosis—A disease because it is characterized by bleeding
Brosens, I. A. (1997) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(97)70482-4 · Cited by 169
Anti-TNF- treatment for deep endometriosis-associated pain: a randomized placebo-controlled trial
Koninckx, P. R., Craessaerts, M., Timmerman, D., Cornillie, F., & Kennedy, S. (2008) · Human Reproduction · doi:10.1093/humrep/den177 · Cited by 165 · cited 4×
“The dissection of the failed clinical trials and the excavation of possible causes for failure can be expedited by published trials, such as the raloxifene (Stratton et al., 2008) and infliximab trials (Koninckx et al., 2008).”
BackgroundInfluentialKettel, L. M., Murphy, A. A., Mortola, J. F., Liu, J. H., Ulmann, A., & Yen, S. S. C. (1991) · Fertility and Sterility · doi:10.1016/s0015-0282(16)54531-2 · Cited by 151 · cited 1×
“Although mifepristone was the first SRPM tested on human endometriosis in 1991 (Kettel et al., 1991), its formal registered trial had to wait for over 20 years (Carbonell et al., 2015).”
BackgroundAdenomyosis: the pathophysiology of an oestrogen-dependent disease
Kitawaki, J. (2006) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2006.01.010 · Cited by 143
Ding, D., Liu, X., Duan, J., & Guo, S.-W. (2015) · Human Reproduction · doi:10.1093/humrep/dev025 · Cited by 139
Self-citationGuo, S.-W., Mao, X., Ma, Q., & Liu, X. (2013) · Fertility and Sterility · doi:10.1016/j.fertnstert.2012.08.038 · Cited by 131 · cited 1×
“, 2010), and its expression correlates with the contractile amplitude in myometrial tissues as well as with the severity of dysmenorrhea in women with adenomyosis (Guo et al., 2013).”
BackgroundŠmuc, T., Pucelj, M. R., Šinkovec, J., Husen, B., Thole, H., & Rižner, T. L. (2007) · Gynecological Endocrinology · doi:10.1080/09513590601152219 · Cited by 124
Shen, M., Liu, X., Zhang, H., & Guo, S.-W. (2015) · Human Reproduction · doi:10.1093/humrep/dev314 · Cited by 124
Self-citationGuo, S.-W. (2018) · Human Reproduction · doi:10.1093/humrep/dey015 · Cited by 116
Self-citationChen, Y., Pei, H., Chang, Y., Chen, M., Wang, H., Xie, H., & Yao, S. (2014) · Journal of Ovarian Research · doi:10.1186/s13048-014-0108-0 · Cited by 116
Liu, X., Zhang, Q., & Guo, S.-W. (2018) · Reproductive Sciences · doi:10.1177/1933719117718275 · Cited by 110
Self-citationWilkens, J., Male, V., Ghazal, P., Forster, T., Gibson, D. A., Williams, A. R. W., Brito-Mutunayagam, S. L., Craigon, M., Lourenco, P., Cameron, I. T., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300958 · Cited by 101
Hormonal therapy for endometriosis: from molecular research to bedside
Tosti, C., Biscione, A., Morgante, G., Bifulco, G., Luisi, S., & Petraglia, F. (2017) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2016.05.032 · Cited by 96
Elevated peritoneal expression and estrogen regulation of nociceptive ion channels in endometriosis
Greaves, E., Grieve, K., Horne, A. W., & Saunders, P. T. K. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2282 · Cited by 89
Guo, S.-W., Ding, D., Shen, M., & Liu, X. (2015) · Reproductive Sciences · doi:10.1177/1933719115570907 · Cited by 86 · cited 1×
“The lack of efficacy that at least some drugs may have could very well be related to the fact that it is becoming increasingly clear that endometriosis and adenomyosis are fibroproliferative diseases rather than endometriumderived disorders (Guo et al., 2015; Zhang et al., 2016a, b, 2017b).”
BackgroundSelf-citationMechsner, S., Bartley, J., Loddenkemper, C., Salomon, D. S., Starzinski-Powitz, A., & Ebert, A. D. (2005) · Fertility and Sterility · doi:10.1016/j.fertnstert.2004.11.038 · Cited by 79 · cited 1×
“, 2017) and lesional smooth muscle cells (Mechsner et al., 2005; Barcena de Arellano et al., 2011), the latter probably resulting from platelet-induced smooth muscle metaplasia (Zhang et al.”
BackgroundPGH2, TxA2 and PGI2 have potent and differentiated actions on human uterine contractility
Wilhelmsson, L., Wikland, M., & Wiqvist, N. (1981) · Prostaglandins · doi:10.1016/0090-6980(81)90145-3 · Cited by 77
Whitaker, L. H. R., Murray, A. A., Matthews, R., Shaw, G., Williams, A. R. W., Saunders, P. T. K., & Critchley, H. O. D. (2017) · Human Reproduction · doi:10.1093/humrep/dew359 · Cited by 77 · cited 3×
“In contrast to UPA, which is associated with endometrial thickening early on (starting at 3 months after taking the drug), the cystic endometrial changes due to PAEC and endometrial thickening (as detected by ultrasound) occurred very late (> 8–12 months) during asoprisnil treatment.”
BackgroundZhang, Q., Liu, X., & Guo, S.-W. (2017) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2016.11.006 · Cited by 76
Self-citationLeonardo-Pinto, J. P., Benetti-Pinto, C. L., Cursino, K., & Yela, D. A. (2017) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2017.02.015 · Cited by 72 · cited 1×
“now the top-of-the-line drug for treating endometriosis, despite the fact that it merely alleviates symptoms, but does not reduce the volume of the endometriotic nodules (Leonardo-Pinto et al., 2017).”
Backgroundvan Kaam, K. J. A. F., Schouten, J. P., Nap, A. W., Dunselman, G. A. J., & Groothuis, P. G. (2008) · Human Reproduction · doi:10.1093/humrep/den153 · Cited by 70
Self-citationDonnez, J., Nisolle, M., Casanas-Roux, F., Brion, P., & DaFerreira, N. C. (1996) · Human Reproduction · doi:10.1093/oxfordjournals.humrep.a019024 · Cited by 65
Data sharing statements for clinical trials
Taichman, D. B., Sahni, P., Pinborg, A., Peiperl, L., Laine, C., James, A., Hong, S.-T., Haileamlak, A., Gollogly, L., Godlee, F., et al. (2017) · BMJ · doi:10.1136/bmj.j2372 · Cited by 62
Yao, Z., Shen, X., Capodanno, I., Donnelly, M., Fenyk-Melody, J., Hausamann, J., Nunes, C., Strauss, J., & Vakerich, K. (2005) · Journal of Investigative Surgery · doi:10.1080/08941930591004412 · Cited by 60 · cited 1×
“Indeed, a rat study clearly demonstrated dose-dependent regression of ectopic endometrium (Yao et al., 2005).”
BackgroundComparison of the effects of raloxifene and anastrozole on experimental endometriosis
Altintas, D., Kokcu, A., Kandemir, B., Tosun, M., & Cetinkaya, M. B. (2010) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2010.02.004 · Cited by 57
Naqvi, H., Sakr, S., Presti, T., Krikun, G., Komm, B., & Taylor, H. S. (2014) · Biology of Reproduction · doi:10.1095/biolreprod.113.114165 · Cited by 54 · cited 2×
“In addition, SERMs block the feedback inhibition of sex steroids on the hypothalamus and pituitary, and the resultant ovarian stimulation and increased estrogen production may have contributed to the failure of the trial (Naqvi et al., 2014).”
BackgroundMethodHuang, M., Li, X., Guo, P., Yu, Z., Xu, Y., & Wei, Z. (2017) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-016-0220-7 · Cited by 52
Hevir, N., Vouk, K., Šinkovec, J., Ribič-Pucelj, M., & Lanišnik Rižner, T. (2011) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2011.01.003 · Cited by 48
Mifepristone 2.5, 5, 10mg versus placebo in the treatment of endometriosis
Carbonell, J. L., Riverón, A. M., Leonard, Y., González, J., Heredia, B., & Sánchez, C. (2016) · Journal of Reproductive Health and Medicine · doi:10.1016/j.jrhm.2015.09.001 · Cited by 25 · cited 12×
“We also have attempted to analyse selected failed clinical trials in the context of published translational/preclinical research and our growing understanding of the natural history of endometriotic/adenomyotic lesions, in the hope that the lessons learned will steer investigators toward the right track in future drug…”
BackgroundInfluentialEndometriosis-Derived Thromboxane A2 Induces Neurite Outgrowth
Yan, D., Liu, X., & Guo, S.-W. (2017) · Reproductive Sciences · doi:10.1177/1933719116670037 · Cited by 17
Self-citation
Cited by
Estrogen Receptors and Endometriosis
Chantalat, E., Valera, M.-C., Vaysse, C., Noirrit, E., Rusidze, M., Weyl, A., Vergriete, K., Buscail, E., Lluel, P., Fontaine, C., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082815 · Cited by 297
Drug repurposing: a systematic review on root causes, barriers and facilitators
Krishnamurthy, N., Grimshaw, A. A., Axson, S. A., Choe, S. H., & Miller, J. E. (2022) · BMC Health Services Research · doi:10.1186/s12913-022-08272-z · Cited by 279
Reis, F. M., Coutinho, L. M., Vannuccini, S., Batteux, F., Chapron, C., & Petraglia, F. (2020) · Human Reproduction Update · doi:10.1093/humupd/dmaa009 · Cited by 166
The Pathogenesis of Adenomyosis vis-à-vis Endometriosis
Guo, S.-W. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9020485 · Cited by 165
“In fact, few drugs are being developed exclusively for adenomyosis [12].”
BackgroundSelf-citationCancer-associated mutations in endometriosis: shedding light on the pathogenesis and pathophysiology
Guo, S.-W. (2020) · Human Reproduction Update · doi:10.1093/humupd/dmz047 · Cited by 96
Self-citation
Metadata
- Authors
- Guo, S.-W., & Groothuis, P. G.
- Venue
- Human Reproduction Update
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-06-11
- Volume
- 24
- Issue
- 5
- Pages
- 577-598
- ISSN
- 1355-4786 (ISSN-L)
- 1460-2369
- OpenAlex
- W2887551760
- Cited by
- 95
- References
- 72
- FWCI
- 8.98
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.